UNLABELLED: AIM/ BACKGROUND: To determine the feasibility and safety of intratumoral α-gal glycolipids injection for conversion of human tumors into autologous Tumor Associated Antigens (TAA) vaccine. α-Gal glycolipids bind anti-Gal--the most abundant antibody in humans. Pre-clinical studies indicated that injected α-gal glycolipids insert into tumor cell membranes, bind anti-Gal and target tumor cells to Antigen Presenting Cells, thereby converting tumors into autologous TAA vaccines. We hypothesized that α-gal glycolipids might have similar utility in humans. PATIENTS AND METHODS: Eleven patients with advanced solid tumors received one intratumoral injection of 0.1 mg, 1 mg, or 10 mg α-gal glycolipids. The primary endpoint was dose-limiting toxicity (DLT) within 4 weeks. Secondary endpoints included long-term toxicity, autoimmunity, radiological tumor response and survival. RESULTS: There were no DLT and no clinical or laboratory evidence of autoimmunity, or any other toxicity. Few patients had an unexpectedly long survival. CONCLUSION: Intratumoral injection of α-gal glycolipids is feasible and safe for inducing a protective anti-tumor immune response.
UNLABELLED: AIM/ BACKGROUND: To determine the feasibility and safety of intratumoral α-gal glycolipids injection for conversion of humantumors into autologous Tumor Associated Antigens (TAA) vaccine. α-Gal glycolipids bind anti-Gal--the most abundant antibody in humans. Pre-clinical studies indicated that injected α-gal glycolipids insert into tumor cell membranes, bind anti-Gal and target tumor cells to Antigen Presenting Cells, thereby converting tumors into autologous TAA vaccines. We hypothesized that α-gal glycolipids might have similar utility in humans. PATIENTS AND METHODS: Eleven patients with advanced solid tumors received one intratumoral injection of 0.1 mg, 1 mg, or 10 mg α-gal glycolipids. The primary endpoint was dose-limiting toxicity (DLT) within 4 weeks. Secondary endpoints included long-term toxicity, autoimmunity, radiological tumor response and survival. RESULTS: There were no DLT and no clinical or laboratory evidence of autoimmunity, or any other toxicity. Few patients had an unexpectedly long survival. CONCLUSION: Intratumoral injection of α-gal glycolipids is feasible and safe for inducing a protective anti-tumor immune response.
Authors: Oliver M T Pearce; Annie N Samraj; Heinz Läubli; Nissi M Varki; Ajit Varki Journal: Proc Natl Acad Sci U S A Date: 2015-02-20 Impact factor: 11.205
Authors: Mark R Albertini; Erik A Ranheim; Cindy L Zuleger; Paul M Sondel; Jacquelyn A Hank; Alan Bridges; Michael A Newton; Thomas McFarland; Jennifer Collins; Erin Clements; Mary Beth Henry; Heather B Neuman; Sharon Weber; Giles Whalen; Uri Galili Journal: Cancer Immunol Immunother Date: 2016-05-20 Impact factor: 6.968
Authors: Stephen M Shaw; Jenny Middleton; Kim Wigglesworth; Amber Charlemagne; Oliver Schulz; Melanie S Glossop; Giles F Whalen; Robert Old; Mike Westby; Chris Pickford; Rinat Tabakman; Irit Carmi-Levy; Abi Vainstein; Ella Sorani; Arik A Zur; Sascha A Kristian Journal: Cancer Cell Int Date: 2019-12-19 Impact factor: 5.722